Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Pharmaceutical company Evgen Pharma reported slightly wider losses as a reduction in payroll costs were offset by increased professional fees and business development costs.
For the year ended 31 March 2020, pre-tax losses widened to £2.7m from £2.6m.
Looking ahead, the company said it would complete its key toxicology and formulation work and the initiation of new clinical trials on SFX-01 in new indications.
'We believe that the value of SFX-01 as a potential drug active in each of the Nrf2 and STAT3 pathways will become increasingly clear and the considerable commercial opportunity this represents recognised,' it added.
At 8:16am: (LON:EVG) Evgen Pharma Plc share price was -0.75p at 10.05p